Thomas T.  Thomas net worth and biography

Thomas Thomas Biography and Net Worth

Mr. Thomas has over 25 years of financial experience in biotechnology, packaged goods, financial services and non-profit organizations. Since 2011, he has been providing financial, investment and risk management consulting services to a variety of technology, beverage and food and biotechnology companies. In 2009, he joined the Stupski Foundation (“Stupski”), a foundation focused on transforming the public education system, as its Chief Financial Officer. In 2010, he was promoted to Chief Operating Officer and served as Stupski’s interim Chief Executive Officer. Prior to joining Stupski, he spent 12 years at Genentech, Inc. (“Genentech”), a biopharmaceutical company, in various financial roles, ultimately serving as the company’s Corporate Treasurer from 2001 to 2006. His executive responsibilities at Genentech included treasury operations, cash and investment management, corporate finance, global procurement, enterprise risk management, business continuity and real estate finance and administration.

Early in his career, he was a manager of financial strategy with Del Monte Foods and he began his career at GE Capital Corporation (“GE”) as an analyst in GE’s corporate finance group, which focused on leveraged buyouts and bankruptcy financing. He currently serves on the board of trustees of the Cancer Prevention Institute of California and has previously served on the boards of the San Francisco Security Analysts and Hospitality House. He is also a mentor in the Ivy Exec Mentorship Network. Mr. Thomas is a Chartered Financial Analyst and received his MBA from the University of Cincinnati, where he was a Graduate Fellow and BA in Music from the University of Cincinnati’s College-Conservatory of Music.

What is Thomas T. Thomas' net worth?

The estimated net worth of Thomas T. Thomas is at least $0.00 as of September 3rd, 2020. Mr. Thomas owns 4,500 shares of Opiant Pharmaceuticals stock worth more than $0 as of March 29th. This net worth approximation does not reflect any other investments that Mr. Thomas may own. Learn More about Thomas T. Thomas' net worth.

How do I contact Thomas T. Thomas?

The corporate mailing address for Mr. Thomas and other Opiant Pharmaceuticals executives is 233 WILSHIRE BLVD. SUITE 280, SANTA MONICA CA, 90401. Opiant Pharmaceuticals can also be reached via phone at (310) 598-5410 and via email at [email protected]. Learn More on Thomas T. Thomas' contact information.

Has Thomas T. Thomas been buying or selling shares of Opiant Pharmaceuticals?

Thomas T. Thomas has not been actively trading shares of Opiant Pharmaceuticals within the last three months. Most recently, Thomas T. Thomas sold 831 shares of the business's stock in a transaction on Tuesday, September 21st. The shares were sold at an average price of $24.12, for a transaction totalling $20,043.72. Learn More on Thomas T. Thomas' trading history.

Who are Opiant Pharmaceuticals' active insiders?

Opiant Pharmaceuticals' insider roster includes Craig Collard (Director), Roger Crystal (CEO), David O'Toole (CFO), Matthew Ruth (Insider), Michael Sinclair (Director), Phil Skolnick (Insider), and Thomas Thomas (Director). Learn More on Opiant Pharmaceuticals' active insiders.

Thomas T. Thomas Insider Trading History at Opiant Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/21/2021Sell831$24.12$20,043.72View SEC Filing Icon  
9/3/2020Buy2,500$8.40$21,000.004,500View SEC Filing Icon  
5/18/2018Sell2,763$16.44$45,423.72View SEC Filing Icon  
5/15/2018Sell4,300$18.35$78,905.00View SEC Filing Icon  
See Full Table

Thomas T. Thomas Buying and Selling Activity at Opiant Pharmaceuticals

This chart shows Thomas T Thomas's buying and selling at Opiant Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Opiant Pharmaceuticals Company Overview

Opiant Pharmaceuticals logo
Opiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. The company was founded on June 21, 2005 and is headquartered in Santa Monica, CA.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $20.58
Low: $20.03
High: $21.10

2 Week Range

Now: N/A

Volume

562,700 shs

Average Volume

77,920 shs

Market Capitalization

$108.83 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.84